Skip to main content
Equibles
DMAC logo

DMAC · DiaMedica Therapeutics Inc. · Metrics

Track DMAC — free

Use DMAC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DMAC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.33 -0.33 (-3.42%) At close · Nov 12 Earnings today Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$503.13M
Shares
53.93M
Volume · Nov 12 187.78K Avg daily vol (3M) 194.88K

DMAC metrics

64 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.33
Market cap
$503.13M

Price action

23 metrics
Price change (1W)
-10.3%
Price change (30D)
+23.5%
Price change (3M)
+41.2%
Price change (6M)
+54.3%
Price change (YTD)
+21.4%
Price change (1Y)
+51.2%
Trailing year
Price change (5Y)
+113.2%
52-week high
$10.77
52-week low
$5.33
Change from 52-week high
-10.3%
Change from 52-week low
+81.2%
Annualized volatility
60.8%
Annualized volatility (3M)
65.3%
Implied volatility (30D)
97.6%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.8
RSI (14D)
57.9
Price vs SMA 50
+19.1%
Price vs SMA 200
+34.8%
Avg volume (3M)
194,145
Relative volume
0.7
Average dollar volume
$1.55M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
53.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
13.6
reciprocal yield 7.4%
FCF yield
-6.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-13
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-1,352.2%
Trailing 12 months
Net margin
-1,146.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$39.23M
Net income (TTM)
−$37.54M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.04

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-97.9%
Return on assets
-83.4%
Debt / equity
0.0
Current ratio
6.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$31.54M
Quick ratio
6.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$43.49M
Latest balance sheet
Cash & equivalents
$5.13M
Total assets
$45.00M
Total debt
$9,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$31.51M
Capital expenditures (TTM)
$33,000
R&D (TTM)
$29.28M
SG&A (TTM)
—
Stock compensation (TTM)
$4.15M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
89
13F filer change QoQ
-11
Institutional ownership
23.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.2%
Private-fund adviser ownership
3.8%
Active holders' share change QoQ
+16.3%
Holder tenure
13.8
Price vs estimated holder cost
+31.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.7%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 24.8 days to cover
Days to cover
24.8d
Short-squeeze score
86 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1401040 CUSIP 25253X207 13F (30d) 47 filings 46 filers Visit website Investor relations